Noninvasive Brain Stimulation: Challenges and Opportunities for a New Clinical Specialty

Abstract

Noninvasive brain stimulation refers to a set of technologies and techniques with which to modulate the excitability of the brain via transcranial stimulation. Two major modalities of noninvasive brain stimulation are transcranial magnetic stimulation (TMS) and transcranial current stimulation. Six TMS devices now have approved uses by the U.S. Food and Drug Administration and are used in clinical practice: five for treating medication refractory depression and the sixth for presurgical mapping of motor and speech areas. Several large, multisite clinical trials are currently underway that aim to expand the number of clinical applications of noninvasive brain stimulation in a way that could affect multiple clinical specialties in the coming years, including psychiatry, neurology, pediatrics, neurosurgery, physical therapy, and physical medicine and rehabilitation. In this article, the authors review some of the anticipated challenges facing the incorporation of noninvasive brain stimulation into clinical practice. Specific topics include establishing efficacy, safety, economics, and education. In discussing these topics, the authors focus on the use of TMS in the treatment of medication refractory depression when possible, because this is the most widely accepted clinical indication for TMS to date. These challenges must be thoughtfully considered to realize the potential of noninvasive brain stimulation as an emerging specialty that aims to enhance the current ability to diagnose and treat disorders of the brain.

EPA guidance on treatment of negative symptoms in schizophrenia

“…Side effects of rTMS were not addressed in the meta-analyses. rTMS is generally considered to have a benign side-effect profile [62] and the largest multicenter trial did not report a higher rate of side effects in the active TMS group [61]. However, Kennedy et al reported a nonsignificant worsening of positive symptoms that became significant in subgroup analyses with stimulation frequency >20 Hz, stimulation intensity >110%, trials lasting over 3 weeks, and treatment site over the left prefrontal cortex [59].…”

Artificial Intelligence, Brains, and Beyond: Imperial College London Neurotechnology Symposium, 2020

“…This is widely used in clinical practice due to its high-level efficiency. 8 However, the invasive nature of DBS limits its accessibility to a small number of medical institutions where neurosurgeons can collaborate with psychiatrists. 9 The development of noninvasive technologies with a simpler procedure is necessary, therefore, to make the treatment of severe psychiatric conditions more affordable for patients.…”

Non-invasive Autonomic Neuromodulation Is Opening New Landscapes for Cardiovascular Diseases

“…Non-invasive neuromodulation provides opportunities for better understanding ANS circuits and neurophysiological responses (Boes et al, 2018). It also provides a potential therapeutic target for the treatment of cardiovascular diseases.…”